The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both
normal and pathological angiogenesis, has revealed innovative therapeutic approaches in …

The immune system regulates angiogenesis in cancer with both pro-and antiangiogenic
activities. The induction of angiogenesis is mediated by tumor-associated macrophages and …

The miR-200 family is well known to inhibit the epithelial–mesenchymal transition,
suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports …

The development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer …

Background Several targeted drugs are approved for treatment of patients with metastatic
renal-cell cancer, but no validated biomarkers are available for prediction of clinical …

Introduction The combination of programmed cell death protein-1 or programmed death-
ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment …

Aerobic exercise training (AET) is an effective adjunct therapy to attenuate the adverse side-
effects of adjuvant chemotherapy in women with early breast cancer. Whether AET interacts …

Antiangiogenic therapies that target VEGF or its receptors have become a mainstay of
cancer therapy in multiple malignancies. However, the clinical efficacy of these agents is …

Background Circulating angiogenic factors are altered in patients with mCRC receiving
bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into …

Angiogenesis is a critical process in the development of tumor malignancy and occurs at
various stages of tumor progression. Interleukin-8 (IL-8) is a pro-angiogenic factor produced …